Using PET imaging to detect early pulmonary arterial hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to utilize 18F-fluoroglutamine (18F-FGln) PET imaging to assess glutamine uptake in patients diagnosed with pulmonary arterial hypertension (PAH) compared to healthy controls. The objective is to develop a non-invasive imaging biomarker that can detect early stages of PAH, which is often misdiagnosed and leads to significant disease progression. The research team, consisting of experts in the field, will conduct in-human imaging to quantify metabolic changes associated with PAH. This pilot experiment seeks to establish the potential of 18F-FGln as a diagnostic tool for early intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Cases:

1. Age between 18-75 years old
2. Confirmed diagnosis of SSc-PAH / SSc-eiPAH/IPAH/ by right heart catheterization. And Scleroderma with no PAH confirmand by echo.

Controls:

1. Age between 18-75 years old
2. Individuals who are at low risk for current or future cardiovascular or pulmonary symptoms or diseases

Exclusion Criteria:

Cases:

1. Smoking
2. Pregnant/ breast feeding women
3. Children under 18
4. Inability to read and understand the informed consent
5. History of CT contrast allergy
6. Inability to lie down for long period of time
7. Having claustrophobic
8. History of radiation exposure at workplace
9. Consuming more than 2-3 alcoholic drinks a week
10. Working previously in any of the following "cool miner, painter, iron miner, Mill worker, asbestos, insulation/heat resistance materials, sand"
11. Any medical conditions involving the heart or lungs that would make participation in the study unsafe in the opinion of the PI.

Controls:

1. Smoking
2. Pregnant/ breast feeding women
3. Children under 18
4. Inability to read and understand the informed consent
5. History of CT contrast allergy.
6. Inability to lie down for long period of time
7. Having claustrophobic
8. History of radiation exposure at workplace
9. Consuming more than 2-3 alcoholic drinks a week
10. Working previously in any of the following "coal miner, painter, iron miner, Mill worker, asbestos, insulation/heat resistance materials, sand"
11. Any medical conditions involving the heart or lungs or that would make participation in the study unsafe in the opinion of the PI.
12. Family history of Pulmonary Hypertension or Scleroderma

Where it's running

• Montefiore Hospital Clinical and Translational Research Center
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Stephen Chan — University of Pittsburgh
• Study coordinator: Yassmin Al Aaraj
• Email: yaa29@pitt.edu
• Phone: 14126479227

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding how low-load leg exercises affect muscle and blood flow in PAH patients

  This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07781709

• Sotatercept in Japanese children with pulmonary arterial hypertension

  This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.

  Recruiting at 3 sites Phase 2 Merck Sharp & Dohme LLC · Izumi, Osaka and 2 other locations · NCT07646860

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

• Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy

  This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.

  Recruiting at 3 sites Phase 4 Merck Sharp & Dohme LLC · Hyderabad, Andhra Pradesh and 2 other locations · NCT07600723

• Once-daily treprostinil palmitil inhalation powder for PAH

  This study tests whether taking a daily inhaled treprostinil palmitil powder for 24 weeks improves exercise ability in adults with pulmonary arterial hypertension compared to a placebo.

  Recruiting at 39 sites Phase 3 Insmed Incorporated · Los Angeles, California and 38 other locations · NCT07481981

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.